Neurent Medical Announces Expanded Access Following Cigna Policy Update for NEUROMARK®
GALWAY, Ireland, June 30, 2025 /PRNewswire/ -- Neurent Medical, a leader in non-surgical treatments for chronic rhinitis, today announced that Cigna Healthcare will provide coverage for NEUROMARK treatment of the posterior nasal nerve by removing CPT 31242 posterior nasal nerve ablation using radiofrequency from its Experimental & Investigational (E&I) list, effective September 15th, 2025.
This policy update is an important step in improving patient access to innovative treatment options for chronic rhinitis and reflects growing payer recognition of the procedure's therapeutic value. This update removes a key barrier that previously limited the ability for ENT physicians to treat Cigna patients using posterior nasal nerve ablation.
"This is a significant moment for ENT providers and patients alike," said Brian Shields, CEO of Neurent Medical. "Cigna's reclassification of CPT 31242 reinforces the evolving understanding of chronic rhinitis and the role of targeted, minimally invasive interventions like NEUROMARK in managing the condition. We are committed to continue building on our large evidence base and working closely with the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) to support adoption across the US healthcare system"
The NEUROMARK System delivers impedance-controlled, low-power radiofrequency (RF) energy to disrupt the parasympathetic nerve signals, addressing key symptoms of Chronic Rhinitis such as persistent nasal congestion and rhinorrhea (runny nose).
"Chronic rhinitis can significantly affect an individual's wellbeing and patients need access to all available, medically sound solutions" said Dr. Peter Manes, Associate Professor at Yale School of Medicine. "This policy update is significant and helps otolaryngologists offer a modern, evidence-supported treatment with fewer administrative hurdles. The large and growing evidence base makes it more difficult for patients to be denied access to such technologies."
Key Points for Providers:
CPT 31242 is no longer classified as investigational by Cigna
Precertification is not required under the updated policy (always confirm benefits per individual plan)
The policy supports more streamlined access to NEUROMARK for eligible patients
To view Cigna's updated medical policy, visit:CIGNA Policy LINK
For more information about NEUROMARK, visit www.neuromark.com or contact your local Neurent Medical Sales Representative.
About Neurent Medical
Neurent Medical is pioneering innovative treatments for chronic inflammatory sinonasal diseases by targeting and safely disrupting hyperactive autonomic nerves that drive underlying inflammation. Its proprietary NEUROMARK® technology, with a unique design and advanced smart algorithmic control, allows physicians to precisely target and safely disrupt multiple underlying nerve branches in a single procedure to alleviate chronic rhinitis symptoms and improve patient quality of life. The venture capital-backed company is headquartered in Galway, Ireland, with US HQ in Braintree, MA. For more information visit www.neuromark.com. PAM225r01
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurent-medical-announces-expanded-access-following-cigna-policy-update-for-neuromark-302494486.html
SOURCE Neurent Medical
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
BNP Paribas Exane Upgrades Novo Nordisk (NVO) to Neutral from Underperform
Novo Nordisk A/S (NYSE:NVO) is one of the top cheap stocks that will go to the moon according to Reddit. On August 13, BNP Paribas Exane upgraded Novo Nordisk A/S (NYSE:NVO) to Neutral from Underperform with a $54 price target. An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. The firm told investors that it sees a more balanced risk/reward now that the company's 'reality' is better reflected in the shares. Novo Nordisk A/S (NYSE:NVO) announced results for the January 1 to June 30 period on August 6, reporting an operating profit growth of 25% in Danish kroner and 29% at constant exchange rates (CER) to DKK 72.2 billion. Management also stated that sales in US Operations rose by 16% in Danish kroner (17% at CER), while sales in International Operations grew by 16% in Danish kroner (19% at CER). Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products. While we acknowledge the potential of XXXX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
5 hours ago
- Yahoo
Cat dementia is similar to human Alzheimer's disease ...Tech & Science Daily podcast
Listen here on your chosen podcast platform. Cats develop dementia similarly to humans with Alzheimer's disease. Scientists hope their findings lead to new treatments for both humans and our feline friends. For more, we spoke to the lead author, Dr Robert McGeachan, at the University of Edinburgh's Royal School of Veterinary Studies. A swarm of jellyfish forced the shutdown of France's largest nuclear power plant, Gravelines. But how unusual is this event? And, Reddit blocks the Internet Archive's Wayback Machine from archiving large portions of its site. Also in this episode: -How blowing through a conch shell could alleviate the symptoms of obstructive sleep apnoea -Lola Young urges Keir Starmer to block Rosebank oil and gas development projects -Natalie the Nerd builds a transparent GameBoy Colour
Yahoo
6 hours ago
- Yahoo
Eli Lilly raising GLP-1 prices abroad raises more questions about US pricing: BofA analyst
Eli Lilly (LLY) raised prices of its GLP-1 weight-loss injectable in the UK this week, with plans to do the same in other European countries, in response to President Trump's push to normalize pricing in peer developed nations. The effort, known as Most Favored Nations pricing, has been a goal of Trump's since his first term. He has doubled down on the efforts this year, giving pharma companies 60 days to implement changes in pricing in what he deems "freeloading" nations. The US drug economy differs from European and other developed nations, which rely on the government to negotiate prices with drugmakers, resulting in lower prices globally. "While we agree that the costs for breakthrough medicines should be more fairly shared across developed countries, we must also address the underlying structural issues in the US that have contributed to high drug prices. The US system is complex and opaque," Lilly said in a statement Thursday. The stock was up 1% in trading Friday. Eli Lilly raised the price of its GLP-1, Zepbound, from about $125 to $165 and plans an additional hike next month that would almost double its price. In a note to clients Friday, Bank of America Securities research analyst Tim Anderson questioned who would actually be impacted by the raised prices. "LLY has announced it will raise GLP-1 pricing in the UK by a healthy margin (a doubling of price, but it's unclear to whom this higher price realistically applies). It expects to do something similar in other European countries (but worth appreciating: in most European markets, there aren't price agreements in place between GLP-1 manufacturers and governments, meaning these are out-of-pocket spending markets)," Anderson wrote. Ultimately, whether or not the move results in lower US prices remains a question, though Anderson believes it likely will not. "Does this mean it will actually cut the price on the GLP-1s in the US (and on other medicines)? To us, the answer is quite likely no, or at least, not in a way that creates P&L [profit and loss planning ] risk," he wrote. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
